Research programme: LPAAT-beta inhibitors - Cell Therapeutics

Drug Profile

Research programme: LPAAT-beta inhibitors - Cell Therapeutics

Alternative Names: CT-32228; LPAAT-B inhibitors research programme - Cell Therapeutics; LPAAT-beta inhibitors research programme - Cell Therapeutics

Latest Information Update: 01 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Therapeutics
  • Class Small molecules
  • Mechanism of Action Lysophosphatidic acid acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 Sep 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 01 Jul 2005 A preclinical study has been added to the cancer pharmacodynamics section
  • 16 Apr 2004 This programme is still in active development - (95th Annual Meeting of the American Association for Cancer Research [AACR-2004])
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top